Results 41 to 50 of about 3,056 (181)

Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J-ADNI Study. [PDF]

Geriatr Gerontol Int
Background Lecanemab and donanemab are recently approved disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD), indicating amyloid positivity, with Mini‐Mental State Examination (MMSE) requirements.
Nakashima S, Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Satake W, Iwatsubo T, Japanese Alzheimer's Disease Neuroimaging Initiative.   +8 more
europepmc   +2 more sources

Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

, 2021
Background Donanemab (LY3002813) is an IgG1 antibody directed at an N-terminal pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques.
Aguiar, G., Fleisher, A. S., Cheng, Y.-J., Mullins, G., Duggan Evans, C., Dage, J. L., Willis, B. A., Ardayfio, P., Lo, A. C., Sims, J. R., Chua, L., Takaichi, G., Lowe, S. L., Ishibai, M., Shcherbinin, S., Gueorguieva, I., AACD Investigators   +16 more
core   +1 more source

Mini review: Prospective therapeutic targets of Alzheimer's disease

Brain Circulation, 2022
Alzheimer's disease is a neurological condition that causes the disruption of neuronal connections in the human brain. It is progressive and targets about 10% of the United States population over the age of 65.3 to date, there is no cure to the disease ...
RuchiMangal, YuchuanDing
doaj   +1 more source

EFFECTIVENESS OF LECANEMAB AND DONANEMAB TREATMENT FOR EARLY ALZHEIMER’S DISEASE [PDF]

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and other pathological factors like neuroinflammation and oxidative stress.
Bartłomiej Siuzdak, Justyna Moszkowicz, Marta Jutrzenka, Karolina Pasierb, Karol Poplicha, Patrycja Kardasz, Martyna Grodzińska, Aleksandra Piech, Maria Ufniarska, Piotr Sobkiewicz, Tomasz Ufniarski, Patrycja Ucieklak   +11 more
core   +1 more source

Lecanemab and Donanemab in Early Alzheimer’s Disease: A Systematic Review of Clinical, Biomarker, and Safety Outcomes

CHRISMED Journal of Health and Research
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. Characterized by amyloid-beta (Aβ) accumulation, tau pathology, and cognitive decline, it has long lacked effective disease-modifying ...
Dharmendra Kumar Gupta, Arunima Chaudhuri   +1 more
doaj   +1 more source

Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis. [PDF]

Alzheimers Dement
INTRODUCTION Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate value-based prices (VBPs) for ...
Hoang MT, Kahn JG, Saha S, Trépel D.
europepmc   +2 more sources

Near‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease

Advanced Science, EarlyView.
Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li   +11 more
wiley   +1 more source

The tale of donanemab: God is in the details

Journal of Alzheimer’s Disease
Alzheimer's disease is a major cause of dementia, that affects approximately 7–8% of people aged 65 years and older (according to WHO & Alzheimer's Disease International) and thus is a major concern in public health world-wide.
Takaomi C Saido, Nobuhisa Iwata
openaire   +3 more sources

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source